Literature DB >> 10782386

Comparative LC-MS and HPLC analyses of selected antiepileptics and beta-blocking drugs.

M E Abdel-Hamid1.   

Abstract

A highly sensitive and specific assay procedure based on the combination of liquid chromatography and mass spectrometry (LC-MS) has been developed for the quantitative analysis of selected antiepileptics (carbamazepine and phenytoin) and beta-blocking drugs (acebutolol, atenolol, pindolol and propranolol) using APCI as an ionization process. The measured concentration range was 100-300 ng ml-1 for all drugs except phenytoin (0.5-1.5 micrograms ml-1). Analysis was based on direct injection of methanolic solutions of drugs into the mass spectrometer with the subsequent elution with a mobile phase consisting of methanol and 1% acetic acid solution (4:1) at a flow rate 1 ml min-1. The mass spectrometer was programmed to permit detection and determination of either fragment or molecular ions of carbamazepine, phenytoin, acebutolol, atenolol, pindolol and propranolol at m/e 194.3, 252.9, 337.2, 267.1, 249.1 and 260.1, respectively. The recorded chromatograms exhibited well-resolved peaks at retention times < 1 min. The peak area was correlated linearly to the drug concentration. Intraday precision gave relative standard deviations in the range 1.75-4.02%. Compared to HPLC, the described LC-MS was faster, more sensitive and specific. Unlike HPLC, LC-MS could be applied to analyze incompletely resolved mixtures. The absolute detection limits for LC-MS and HPLC were 0.2-0.5 and 10-25 ng, respectively. Recovery studies of the investigated compounds in pharmaceutical products using LC-MS and HPLC gave mean percentages of 97.5-102.0 and 98.4-103.3, respectively. Statistical analysis of the data using t- and F-tests showed insignificant differences between both methods for the analysis of carbamazepine, phenytoin, acebutolol and atenolol in pharmaceutical formulations. However, LC-MS gave more accurate results than HPLC for determination of pindolol in tablets. Propranolol could only be determined in tablets using LC-MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782386     DOI: 10.1016/s0014-827x(00)00006-9

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  7 in total

1.  De Novo Design and Implementation of a Tandem Acyl Carrier Protein Domain in a Type I Modular Polyketide Synthase.

Authors:  Zilong Wang; Saket R Bagde; Gerardo Zavala; Tsutomu Matsui; Xi Chen; Chu-Young Kim
Journal:  ACS Chem Biol       Date:  2018-10-24       Impact factor: 5.100

Review 2.  Quantitative bioanalytical and analytical method development of dibenzazepine derivative, carbamazepine: A review.

Authors:  Prasanna A Datar
Journal:  J Pharm Anal       Date:  2015-03-09

3.  Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.

Authors:  Charles R Goodlett; Megan Stringer; Jonathan LaCombe; Roshni Patel; Joseph M Wallace; Randall J Roper
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

Review 4.  Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine.

Authors:  Vanessa P Gaspar; Sahar Ibrahim; René P Zahedi; Christoph H Borchers
Journal:  J Mass Spectrom       Date:  2021-11-04       Impact factor: 1.982

5.  Quantitative analysis of propranolol hydrochloride by high performance thin layer chromatography.

Authors:  Girija Bhavar; V A Chatpalliwar
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

6.  A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation.

Authors:  Syed Sarim Imam; Abdul Ahad; Mohammed Aqil; Yasmin Sultana; Asgar Ali
Journal:  J Pharm Bioallied Sci       Date:  2013-01

7.  Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release.

Authors:  Rebecca Chamberlain; Hellen Windolf; Bjoern B Burckhardt; Jörg Breitkreutz; Björn Fischer
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.